Fig. 4: Line plot of mean change in CSFT from baseline by visit up to Week 64. | Eye

Fig. 4: Line plot of mean change in CSFT from baseline by visit up to Week 64.

From: TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration

Fig. 4

Secondary endpoint. ANOVA Analysis of variance, CI confidence interval, CSFT central subfield thickness, LOCF last observation carried forward, LS least squares, SE standard error. ANOVA baseline CSFT categories (<400 μm, ≥400 μm), age categories (<75 years, ≥75 years) and treatment as fixed effects. If Week 28/60 CSFT value is not available, Week 30/62 CSFT is used, otherwise LOCF is used.

Back to article page